Kakyung Kim

Archives
Log in
Subscribe
October 24, 2026

๐Ÿ“ˆ econ-radar 2026-10-24 ยท mRNA ๊ฐœ์ธ๋งž์ถค ํ•ญ์•”๋ฐฑ์‹ (Personalized mRNA Cancer Vaccine)

๐Ÿ“ˆ econ-radar 2026-10-24 ยท mRNA ๊ฐœ์ธ๋งž์ถค ํ•ญ์•”๋ฐฑ์‹ (Personalized mRNA Cancer Vaccine)

๐Ÿ“ˆ econ-radar ๋ฐ์ผ๋ฆฌ

2026-10-24

์ œ์•ฝยท๋ฐ”์ด์˜คยทAI์— ๋ฌด๊ฒŒ๋ฅผ ๋‘” ๊ฒฝ์ œ ๋ฐ์ผ๋ฆฌ โ€” ์‚ฐ์—…๊ตฌ์กฐยทํˆฌ์žยท์‹œ์žฅ 3๋ Œ์ฆˆ

At a Glance

๐Ÿ’Š mRNAยทADCยทBiTE ์„ธ ๊ฐ€์ง€ ๋ชจ๋‹ฌ๋ฆฌํ‹ฐ(modality)์˜ Phase 3 ๋ฐ์ดํ„ฐ๊ฐ€ ํ•˜๋ฃจ์— ์Ÿ์•„์ง„ ESMO ์—ญ๋Œ€๊ธ‰ ๋ฐ์ดํ„ฐ ๋ฐ์ด์˜€๋‹ค. ๊ฐœ์ธ๋งž์ถค mRNA ์•”๋ฐฑ์‹ ์ด 1,137๋ช… ๊ทœ๋ชจ Phase 3์—์„œ ์ฒ˜์Œ์œผ๋กœ ๋‘ ๊ฐ€์ง€ 1์ฐจ ํ‰๊ฐ€๋ณ€์ˆ˜๋ฅผ ๋ชจ๋‘ ์ถฉ์กฑํ–ˆ๋‹ค.

๐Ÿค– Meta AI capex ์‡ผํฌ์˜ ์—ฌํŒŒ๊ฐ€ ๊ฐ€์‹œ๊ธฐ ์ „, 10์›” 28์ผ AlphabetยทMicrosoftยทSKํ•˜์ด๋‹‰์Šค ์‹ค์ ๊ณผ FOMC ๊ฒฐ์ •์ด ํ•œ๊บผ๋ฒˆ์— ์Ÿ์•„์ง„๋‹ค. AI ์ธํ”„๋ผ ํˆฌ์ž ์ง€์†์„ฑ์„ ์‹ค์ ์œผ๋กœ ํ™•์ธํ•˜๋Š” ์ฃผ๊ฐ„์ด๋‹ค.

๐Ÿ› ์—ฐ์ค€ Warsh ์˜์žฅ์€ ๋™๊ฒฐ ๊ธฐ์กฐ๋ฅผ ์žฌํ™•์ธํ•˜๋ฉด์„œ๋„ "์ถ”๊ฐ€ ์ธ์ƒ์ด ์—ด๋ ค์žˆ๋‹ค"๋Š” ์ž…์žฅ์„ ์œ ์ง€ํ–ˆ๋‹ค. 10์›” 29์ผ PCE์™€ GDP Q3 ์ฒซ ์ถ”์ •์น˜๊ฐ€ ๋‹ค์Œ ๊ฒฝ๋กœ๋ฅผ ๊ฐ€๋Š ํ•  ์‹ค๋งˆ๋ฆฌ๋ฅผ ์ œ๊ณตํ•œ๋‹ค.

Today's Top 5

mRNABio

1. INTerpath-001 Phase 3 โ€” mRNA ๊ฐœ์ธ๋งž์ถค ํ•ญ์•”๋ฐฑ์‹  ์„ธ๊ณ„ ์ตœ์ดˆ ๋Œ€๊ทœ๋ชจ Phase 3 ๊ฒ€์ฆ ์„ฑ๊ณต

Moderna์™€ MSD๋Š” ์ธํ‹ฐ์Šค๋ฉ”๋ž€ ์˜คํ† ์  (intismeran autogene)+ํ‚คํŠธ๋ฃจ๋‹ค(pembrolizumab) ๋ณ‘์šฉ์˜ Phase 3 INTerpath-001 ์ „์ฒด ๊ฒฐ๊ณผ๋ฅผ ESMO 2026 LBA1์—์„œ ๊ณต๊ฐœํ–ˆ๋‹ค. ๋ฌด์žฌ๋ฐœ์ƒ์กด(RFSยทrecurrence-free survival) ์œ„ํ—˜๋น„(hazard ratio) 0.58(95% CI 0.45~0.75, p<0.001)(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”), ์›๊ฒฉ์ „์ด๋ฌด์ง„ํ–‰์ƒ์กด(DMFS) HR 0.62(p=0.002)(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”). 2๋…„ RFS์œจ์€ 82.2%(๋ณ‘์šฉ) ๋Œ€ 70.0%(ํ‚คํŠธ๋ฃจ๋‹ค ๋‹จ๋…)(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”), N=1,137๋ช…, Stage IIB~IV ์™„์ „ ์ ˆ์ œ ํ‘์ƒ‰์ข…. NEJM์— ๋™์‹œ ๊ฒŒ์žฌ๋๋‹ค. Phase 2b(KEYNOTE-942) HR 0.51 ๋Œ€๋น„ Phase 3์—์„œ 0.58๋กœ ์†Œํญ ํฌ์„๋์ง€๋งŒ ํ†ต๊ณ„ ์œ ์˜์„ฑ์€ ์œ ์ง€๋๋‹ค. ํˆฌ์—ฌ ํ›„ ์ฒซ 6๊ฐœ์›”๊ฐ„ RFS HR์€ 0.99๋กœ ๋‘ ๊ตฐ ์ฐจ์ด๊ฐ€ ์—†์—ˆ๊ณ , 6๊ฐœ์›” ์ดํ›„ ๊ตฌ๊ฐ„์—์„œ HR 0.42(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”)๋กœ ํฌ๊ฒŒ ๋ฒŒ์–ด์กŒ๋‹ค. ์ „์ฒด์ƒ์กด(OS)์€ ์•„์ง ๋ฏธ์„ฑ์ˆ™ ์ƒํƒœ๋‹ค.

โ†— CancerNetwork(10/24)

Bio

2. DeLLphi-305 LBA3 โ€” ํƒ€๋ฅผ๋ผํƒ€๋ง™+๋”๋ฐœ๋ฃจ๋ง™ ES-SCLC 1์ฐจ ์œ ์ง€์š”๋ฒ• Phase 3 OSยทPFSยทORR ๋‹ฌ์„ฑ

Amgen๊ณผ AstraZeneca๋Š” ํƒ€๋ฅผ๋ผํƒ€๋ง™(tarlatamab, Imdelltra)๊ณผ ๋”๋ฐœ๋ฃจ๋ง™(durvalumab, Imfinzi) ๋ณ‘์šฉ์˜ Phase 3 DeLLphi-305 ์ „์ฒด ๊ฒฐ๊ณผ๋ฅผ ESMO 2026 LBA3์—์„œ ๊ณต๊ฐœํ–ˆ๋‹ค. ๊ด‘๋ฒ”์œ„ ์†Œ์„ธํฌํ์•”(ES-SCLC) 1์ฐจ ์œ ๋„์š”๋ฒ•(๋ฐฑ๊ธˆ ๊ธฐ๋ฐ˜ ํ™”ํ•™์š”๋ฒ•+๋”๋ฐœ๋ฃจ๋ง™) ์™„๋ฃŒ ํ›„ ์œ ์ง€์š”๋ฒ•์œผ๋กœ OSยทPFSยทORR ์„ธ ๊ฐ€์ง€ ํ‰๊ฐ€๋ณ€์ˆ˜๋ฅผ ๋ชจ๋‘ ์ถฉ์กฑํ–ˆ๋‹ค. N=563๋ช…, ๋‡Œ์ „์ด ํ—ˆ์šฉ. ์•ˆ์ „์„ฑ์€ ๊ธฐ์กด ๊ฐœ๋ณ„ ์•ฝ์ œ ํ”„๋กœํŒŒ์ผ๊ณผ ์ผ์น˜ํ–ˆ๊ณ  ์‹ ๊ทœ ์ด์ƒ์‹ ํ˜ธ๋Š” ์—†์—ˆ๋‹ค. OSยทPFS์˜ ๊ตฌ์ฒด์  HR๊ณผ p๊ฐ’์€ ์˜ค๋Š˜ ๊ณต๊ฐœ ๋ณด๋„์—์„œ ๋ฏธํ™•์ธ๋๋‹ค โ€” AmgenยทAstraZeneca ๊ณต์‹ ๋ณด๋„์ž๋ฃŒ ์ถ”๊ฐ€ ํ™•์ธ์ด ํ•„์š”ํ•˜๋‹ค.

โ†— Amgen ๋ณด๋„์ž๋ฃŒ(9/8)

ADC

3. IBI343 G-HOPE-001 OS ํ™•์ธ [ํ›„์†] โ€” CLDN18.2 ADC ์œ„์•” 3์ฐจ ์น˜๋ฃŒ OS HR 0.57

Innovent Biologics์™€ Takeda์˜ ์•„๋ฅด์ฝ”ํƒ€ํˆฌ๊ทธ ํƒ€๋ฐ”ํ…Œ์นธ(arcotatug tavatecan, IBI343/TAK-921)์ด ์–ด์ œ(10/23) ESMO 2026 LBA77์—์„œ ๊ณต๊ฐœํ•œ Phase 3 G-HOPE-001 ์ „์ฒด ๊ฒฐ๊ณผ๊ฐ€ ์˜ค๋Š˜ ์–ธ๋ก  ๋ณด๋„๋กœ ํ™•์ธ๋๋‹ค. ์ „์ฒด์ƒ์กด(OS) HR 0.57(95% CI 0.45~0.73, p<0.0001)(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”). ์ค‘์•™ OS๋Š” IBI343๊ตฐ 10.2๊ฐœ์›”, ์˜์‚ฌ ์„ ํƒ ํ™”ํ•™์š”๋ฒ•(TPC)๊ตฐ 6.9๊ฐœ์›”๋กœ 3.3๊ฐœ์›” ์—ฐ์žฅ๋๋‹ค(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”). N=464๋ช…, CLDN18.2 ์–‘์„ฑยทHER2 ์Œ์„ฑ ์œ„/์œ„์‹๋„์ ‘ํ•ฉ๋ถ€(GEJ) ์„ ์•”์ข… 3์ฐจ ์ด์ƒ ์น˜๋ฃŒ. ์ค‘๊ตญ ๊ตญ๊ฐ€์•ฝํ’ˆ๊ฐ๋…๊ด€๋ฆฌ๊ตญ(NMPA)์ด ์šฐ์„ ์‹ฌ์‚ฌ๋ฅผ ์ˆ˜๋ฆฌํ–ˆ๊ณ , Takeda๋Š” ์ผ๋ณธ ์‹ ์ฒญ์„ ๊ฒ€ํ†  ์ค‘์ด๋‹ค. PFS HR์€ ํ˜„์žฌ ๋ฏธํ™•์ธ์ด๋‹ค.

โ†— OncLive(10/23)

Macro

4. ๋น…ํ…Œํฌ ์–ด๋‹์Šค+FOMC D-4 โ€” 10์›” 28์ผ, ์ด๋ฒคํŠธ ๋ฐ€๋„ ์ตœ๊ณ ์กฐ

10์›” 28์ผ ํ•˜๋ฃจ์— FOMC ๊ธˆ๋ฆฌ ๊ฒฐ์ •(๋™๊ฒฐ ํ™•๋ฅ  ์•ฝ 85%, ํ˜„ํ–‰ 3.75~4.00% ์œ ์ง€ ๊ธฐ๋Œ€), AlphabetยทMicrosoft Q3 ์‹ค์ , SKํ•˜์ด๋‹‰์Šค Q3 ์‹ค์ (KST 09:00)์ด ๊ฒน์นœ๋‹ค. 10์›” 29์ผ์—๋Š” ๋ฏธ๊ตญ GDP Q3 ์ฒซ ์ถ”์ •์น˜(~2.2~2.3%, PIIE ์ถ”์ •)์™€ 9์›” PCE ์ธํ”Œ๋ ˆ์ด์…˜์ด ๋ฐœํ‘œ๋œ๋‹ค. Meta Q3 AI capex ์‡ผํฌ(10/22) ์ดํ›„ AI ์ธํ”„๋ผ ํˆฌ์ž ์ง€์†์„ฑ์— ์˜๋ฌธ์ด ์Œ“์ธ ์ƒํƒœ์—์„œ, Alphabet Google Cloud(Q2 +82% YoY)์™€ Microsoft Azure AI์˜ Q3 ์„ฑ์žฅ๋ฅ  ์—ฐ์†์„ฑ์ด ์ด๋ฒˆ ์ฃผ ์ตœ๋Œ€ ํ™•์ธ ํฌ์ธํŠธ๋‹ค. SKํ•˜์ด๋‹‰์Šค ์˜์—…์ด์ต ์ปจ์„ผ์„œ์Šค๋Š” ์•ฝ 77์กฐ์›(FnGuide ๊ธฐ์ค€)์œผ๋กœ, HBM4(4์„ธ๋Œ€ ๊ณ ๋Œ€์—ญํญ๋ฉ”๋ชจ๋ฆฌ) Q3 ์ถœํ•˜ ๋ฐ˜์˜ ์—ฌ๋ถ€๊ฐ€ ์ดˆ์ ์ด๋‹ค.

โ†— TipRanks(10/22)

BioMarket

5. HLB ๋ฆฌํ”ฝํˆฌ โ€” ๊ตญ์‚ฐ ์ฒซ FDA ์ง์ ‘ ์Šน์ธ ํ•ญ์•” ์‹ ์•ฝ, Q4 ๋ฏธ๊ตญ ์ถœ์‹œ ์ค€๋น„

HLB ๋ฏธ๊ตญ ์žํšŒ์‚ฌ ์—˜๋ ˆ๋ฐ” ํ…Œ๋ผํ“จํ‹ฑ์Šค(Elevar Therapeutics)์˜ ๋ฆฌ๋ผํ‘ธ๊ทธ๋ผํ‹ฐ๋‹™(lirafugratinib, ๋ฆฌํ”ฝํˆฌยทLyrfigtu)์ด 2026๋…„ 9์›” 23์ผ FDA ์Šน์ธ์„ ๋ฐ›์•˜๋‹ค. FGFR2(์„ฌ์œ ์•„์„ธํฌ์„ฑ์žฅ์ธ์ž์ˆ˜์šฉ์ฒด 2) ์œ ์ „์ž ์œตํ•ฉยท์žฌ๋ฐฐ์—ด์ด ํ™•์ธ๋œ ์ „์ด์„ฑ ๋‹ด๊ด€์•”(cholangiocarcinoma) 2์ฐจ ์น˜๋ฃŒ์ œ๋กœ, ๊ตญ๋‚ด ์ œ์•ฝ๋ฐ”์ด์˜ค ๊ธฐ์—…์ด ํ•ญ์•” ์‹ ์•ฝํ—ˆ๊ฐ€์‹ ์ฒญ(NDA)์„ FDA์— ์ง์ ‘ ์ œ์ถœํ•ด ์Šน์ธ๋ฐ›์€ ์ฒซ ์‚ฌ๋ก€๋‹ค. ์ž„์ƒ(ReFocus 1ยท2์ƒ)์—์„œ ๊ฐ๊ด€์  ๋ฐ˜์‘๋ฅ (ORR) 46.5%, ์ „์ฒด์ƒ์กด ์ค‘์•™๊ฐ’(mOS) 22.8๊ฐœ์›”์ด ํ™•์ธ๋๋‹ค. 2026๋…„ 4๋ถ„๊ธฐ ๋ฏธ๊ตญ ์ถœ์‹œ๋ฅผ ๋ชฉํ‘œ๋กœ ์ค€๋น„ ์ค‘์ด๋ฉฐ, 10์›”์—๋Š” ๋น…ํŒŒ๋งˆ ํ˜‘๋ ฅยท๋ณ‘์šฉ ๊ฐœ๋ฐœ ๊ฐ€๋Šฅ์„ฑ์ด ์ƒˆ๋กญ๊ฒŒ ๋ถ€๊ฐ๋๋‹ค๋Š” ๋ณด๋„๊ฐ€ ๋‚˜์™”๋‹ค.

โ†— MTN(9/24)

๐Ÿ—ฃ ์˜ค๋Š˜์˜ ํ™”์ œ

mRNA ๊ฐœ์ธ๋งž์ถค ํ•ญ์•”๋ฐฑ์‹ ์€ ํ™˜์ž ์ข…์–‘์˜ ๋Œ์—ฐ๋ณ€์ด๋ฅผ RNA๋กœ ๋ฒˆ์—ญํ•ด ๋ฉด์—ญ๊ณ„๋ฅผ ํ›ˆ๋ จ์‹œํ‚ค๋Š” ๋ฐฉ์‹์œผ๋กœ, Phase 3์—์„œ ์ฒ˜์Œ์œผ๋กœ ๋Œ€๊ทœ๋ชจ ๊ฒ€์ฆ์— ์„ฑ๊ณตํ–ˆ๋‹ค. OS ์„ฑ์ˆ™๊ณผ ์ง€๋ถˆ์ž ์ˆ˜์šฉ์ด ์ƒ์—…ํ™” ์†๋„๋ฅผ ๊ฒฐ์ •ํ•œ๋‹ค.

์ „์ฒด ๋ฆฌํฌํŠธ ๋ณด๊ธฐ โ†’

Deep Dive ยท Demand ยท Investment ยท Companies ยท Sources ์ „์ฒด๋Š” ์œ„ ๋งํฌ์—์„œ ๋ณด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ…”๋ ˆ๊ทธ๋žจ @econradar ๋กœ๋„ ๋ฐ›๊ธฐ

econ-radar ยท 2026-10-24

ํˆฌ์ž ์ฐธ๊ณ ์šฉ ์ •๋ณด์ž…๋‹ˆ๋‹ค. ์ตœ์ข… ํŒ๋‹จ๊ณผ ์ฑ…์ž„์€ ๋ณธ์ธ์—๊ฒŒ ์žˆ์Šต๋‹ˆ๋‹ค.

Don't miss what's next. Subscribe to Kakyung Kim:
โ† Newer ๐Ÿ“ˆ econ-radar 2026-10-25 ยท MET ์ฆํญ๊ณผ EGFR ๋‚ด์„ฑ(MET Amplification) Older โ†’ ๐Ÿ“ˆ econ-radar 2026-10-23 ยท CLDN18.2์™€ ADC: ์œ„์•” ํ‘œ์ ์น˜๋ฃŒ์˜ ์ƒˆ ์ง€๋„(Claudin 18.2 ADC in gastric cancer)
Powered by Buttondown, the easiest way to start and grow your newsletter.